Introduction
Thank you very much, Professor Ishii. It is a great pleasure to be at Keio University again in such nice fine weather. I know I will enjoy my visit and your hospitality as I have done in the past.
In my lecture today, I will firstly cover the initial observations of H. pylori because controversies that developed in 1983 are still relevant to H. pylori today.
To the young investigators in the audience, I suggest that you should always keep your rejection letters. One from my collection reads, "Dear Dr. Marshall, I regret that your research paper was not accepted for presentation. The number of abstracts we receive continues to increase. For this meeting 67 were submitted and we could only accept 56." So you can imagine that in 1983 we were very depressed about our first failed attempt to present our work on H. pylori.
For the next 10 years, most gastroenterologists believed that H. pylori was a commensal. To demonstrate that H. pylori was a pathogen, we had to show 1) an association with disease, 2) evidence for an immune reaction, 3) an improved clinical outcome after eradication 4) an absence of benefit and 5), that healthy people did not have H. pylori.
The fifth task was a problem because epidemiologic studies revealed that many people-50 percent of the Japanese population for example-carried H. pylori, but were apparently healthy.' Although the pathologist looking at the biopsy of the stomach can see that gastritis is present, it is true that most people with H. pylori are clinically well. This fact is still the main paradox for H. pylori disease.
Dr. Robin Warren's initial observation of curved gastric bacteria was made on 12th June 1979 (his 40th birthday). A photocopy of his original histology report from that day is published in the book called Heli- There are occasional reports linking other Helicobacters to human disease. For example, H. pullorum and H. bilis associated with gall-bladder cancer in one Chilean PCR study.' H. cinaedi, a commensal of hamsters, has been shown to cause rare cases of colitis in immunosuppressed patients.' However, these reports are often difficult to substantiate, and, although new Helicobacters are being described annually, H. pylori is still the most important proven pathogen of the genus. Today it is quite straightforward to classify new Helicobacters by their 16S RNA sequence.
patients with H. pylori though, the stomach appears 100% normal.
In most laboratories, the tollllidine blue or Giemsa stain can be used to demonstrate H. pylori in gastric tissue. The gastric histology related to H. pylori is called active chronic gastritis. If the gastroenterologist takes the biopsy from the border of the ulcer, inflammation caused by the healing process might be confused with gastritis. So the diagnostic biopsy for H. pylori should be taken three or four centimeters away from the ulcer. Gastritis is present in 100 percent of patients with H. pylori, regardless of toxin production. All H. pylori infections cause gastritis but quite often the infected stomach appears normal endoscopically.
For the clinical microbiologist, H. pylori is easily identified as a gram negative curved organism that is catalase, oxidase and rapid urease positive. As with Stapylococcus aureus, the presence of strong catalase activity may protect H. pylori because catalase-positive organisms survive longer after phagocytosis.
In Australia, we diagnose 200,000 cases of H. pylori per annum using the same methods which are used in Japan. We believe there are four million infected persons in Australia -about 20% of the population.' Comparison of various diagnostic tests reveals that serology is the simplest test for general practice. In Australia serology costs about AUD$25. The urea breath test (UBT) is simple but, of course, the patient has to be fasting, so it is not always possible to do the test immediately. In most countries the urea UBT is reimbursed for patients with a history of peptic ulcer and costs AUD$65. Feces antigen is a convenient test for small children, but adult patients prefer the breath test, for about the same cost. For the gastroenterologist, the biopsy urease test costs about AUD$10 but it gives results in one hour. The rapid result makes the test very useful as treatment may be commenced immediately. Culture takes seven days and costs about AUD$80. Histology takes about two days and costs about AUD$100. The advantage of histology, especially in research, is that it does provide a permanent record. You can cut further sections, perform immunological stains, or even extract DNA for molecular studies. The combination of histology and a rapid urease test, such as a CLOtestR"', is the most widely accepted reference method for any H. pylori diagnostic study. Specimens preserved in CLOtests® can also be used for later PCR studies. So if the doctor only performs a urease test, you can use that specimen for PCR, even after many months.
Epidemiology
In Australia and most developed countries, H. pylori infection before the age of 15 years is uncommon. The increased prevalence of H. pylori in older persons, as high as 60% in Japan, is caused by infection acquired in childhood by the faecal oral route, before 1960 when hygiene was less perfect than it is today.'° Pathophysiology Addressing mechanisms of the pathogenesis, I was often asked, "How does H. pylori cause a duodenal ulcer? After all, most of the H. pylori is in the stomach."
Several anatomists had reported that the gastric mucosa could grow into the duodenum where it was referred to as "gastric metaplasia".9
In cases of duodenal ulcer, but also in normal persons, we found islands of gastric metaplasia in the duodenal bulb. These islands make the proximal duodenum extremely susceptible to the effects of H. pylori. The high acid secretion noted in some duodenal ulcer patients is possible because gastritis only results in very superficial colonization of the acid-secreting corpus mucosa.
Contrast this with gastric ulcer patients, in whom acid secretion is lower because the gastritis is more widespread and the mucosal damage from gastritis is more severe. Gastric ulcer tends to occurs at the functional area between the antrum and the corpus, at locations of mixed intestinal and gastric-type mucosa. Histologically, the borders of duodenal ulcers and gastric ulcers look quite similar because they both tend to have this mixture of gastric (metaplasia) and intestinal (metaplasia) tissue types.
Some patients have a duodenal ulcer when they are young when they have high acid secretion, but suffer from gastric ulcer when they are older as worsening gastritis leads to lower acid secretion.
In the duodenal ulcer patient, there is usually far more neutrophil infiltration in the duodenum than in the stomach. It seems that the mucosa cannot perform both conflicting functions of a) withstanding acid attack and b) also allowing neutrophils to pass through to the lumen. Acid and digestive enzymes therefore penetrate the leaky mucosa and the peptic ulcer is created.
Changes in acid secretion, particularly high acid secretion, are well described in patients with duodenal ulcer. This occurs because gastrin secretion is slightly higher than average in patients with H . pylori. Normally, the antral G cell secretes gastrin , a short-lived hormone which stimulates the parietal cell to make acid. Gastric pH is sensed by the antral D cell , which produces somatostatin, a locally acting hormone, to turn off the gastrin. Unfortunately , when H. pylori causes gastritis, the inflammation destroys D cells so that there is less inhibition, more gastrin, and more acid. Patients with duodenal ulcer typically will secrete acid during the night when the stomach is empty be- 
Disease Associations
As shown in Fig. 1 gastric ulcer, non-ulcer dyspepsia -cancer risk may be inversely related to acid secretion. In Japan, the reason that stomach cancer is common may be the combined effects of H. pylori, low acidity, dietary interactions, and even genetic predisposition.
Other Diseases
Other diseases have been suggested but not proven to be H. pylori-related. This issue causes an ongoing controversy."
Increased cardiovascular disease and also growth retardation have been associated with H. pylori." These are difficult to separate from socioeconomic risk factors. Halitosis may be present in some patients, perhaps related to the achlorhydria which can occur allowing food to putrefy in the stomach. I believe 30% of chronic halitosis is caused by H. pylori but it is often impossible to separate H. pylori halitosis from other causes since all respond to the heavy antibiotic regimens used to treat H. pylori. Iron deficiency has been related to H. pylori in many studies so asymptomatic gastritis might be considered at the end of a negative workup for more serious causes of anaemia. Raynaud's disease, migraine headaches, Parkinson's disease, and idiopathic thrombocytopenic purpura are also receiving attention.15 Regardless of the exact mechanism involved, H. pylori certainly does cause a chronic, lifelong stimulation of the immune system, so the potential exists for immune diseases to be initiated by H. pylori infection.' s The VacA and CagA Toxins of H. pylori To examine the pathogenesis of H. pylori disease in more detail, one must understand the cagA Pathogenecity Island (PAI). Whereas the vacA (vacuolating toxin) gene codes for a secreted toxin that causes vacuoles in epithelial cells, the Cag-PAI triggers interleukin-8 (IL-8) secretion, a neutrophil attractant. In addition, the Cag-PAI is a type IV bacterial secretion system. Type IV secretion systems were first identified in a bacterium called Agrobacterium tumefaciens .l 7 This prototype organism is used in plant molecular biology to inject new genes into plants. Similarly, the type IV secretion system represented by H. pylori's Cag-PAI injects CagA protein into the gastric mucosal cells. In strains with Cag-PAI, all aspects of H. pyloriassociated disease appear to be more severe. Knowing this has allowed several groups to patent components of this secretion system as potential vaccine targets . The two most likely antigens are CagA and CagE . CagE is an ATPase responsible for powering the Cag-PAI injection mechanism.' 8 Thus, a vaccine or drug which could disable the CagE, might also cause CagA not to be secreted and thus would disable the harmful CagA effect.
Separate, but related to the Cag-PAI is VacA . VacA is a toxin that creates pores in the epithelial cells . These pores allow urea to pass out through the cells. To use the urea as an alkalinization mechanism, H. pylori has a urea-specific pore called Urel in its own cell wall that allows urea into the bacterial cell." Because UreI is essential for colonization of the gastric mucosa it is yet another potential vaccine target. Fifty-five percent of H. pylori genes have homologues in other life forms, but at least 23% are unique to H. pylori.22 So this 23% of genes in H. pylori should be specific for survival in the stomach. By studying these "gastric" genes, we are certain to learn a lot about gastric mucosa. For example, we might better understand how organisms attach to the enteric mucosa or how H. pylori evades the mucosal immune system.
Gene arrays are now available that represent the complete H. pylori genome. Of course you can also obtain subsets of the human or mouse genome on a chip. This allows a typical experiment in which cells infected with H. pylori expressing Cag-PAI or a Cagnegative control strain of H. pylori. On the array, it is possible to see which genes of the mammalian genome are being activated or suppressed by the Cag-PAI.
With this strategy, we can identify factors in H. pylori and in humans, which determine the outcome of H. pylori disease. One can potentially identify strains of H. pylori that are less harmful, and possibly even "good"! Can H. pylori do Good? Can Eradication of H. pylori be Bad?
There has arisen a controversy related to "good" vs. "bad" H . pylori as a result of a paper by Nyren et al in Sweden entitled "Symptomatic Gastroesophageal Reflux as a Risk Factor of Esophageal Cancer".23 This article showed that acid reflux in the esophagus is a risk factor for adenocarcinoma in the esophagus. If the patients had complained of heartburn or reflux at least once a week the relative risk of adenocarcinoma in the esophagus was 7.7-10.8 times the control group without heartburn. This implied that factors which raised acid levels, even from low levels back up to normal, might increase esophageal adenocarcinoma risk. This paper alarmed gastroenterologists, particularly in the United States. They had noted an increased incidence of adenocarcinoma of the esophagus." Was the decline in H. pylori partially responsible for the rising incidence of esophageal adenocarcinoma?
In an attempt to explain the relationships between H. pylori, acid secretion, and stomach cancer, the following hypothesis has been developed: If you acquire H. pylori at a very young age, the gastric mucosa is damaged. Damage is particularly severe if nutrition is poor. As a result of these adverse events, acid secretion is too low for peptic ulcer to occur, but cancer risk is increased. If you acquire H. pylori after the age of five years, then the corpus mucosa is spared the severe injury. Acid secretion is normal or high, and you are susceptible to ulcer disease, but less likely to develop stomach cancer.
We know that H. pylori is disappearing in Japan. High technology and attention to hygiene have largely protected young children from the infection. So there is less fecal-oral transmission of H. pylori in Japan." However, declining H. pylori and improved nutrition are probably raising the acid secretion level of the whole Japanese population. Maybe this will cause more acid reflux disease and, subsequently, more adenocarcinoma of the esophagus. American gastroenterologists have suggested that reflux disease has increased in the USA because the prevalence of H. pylori has declined."
So is there a downside to H. pylori eradication? Maybe the Cag-PAI strains protect us from reflux and from adenocarcinoma of the lower esophagus. But what is worse? The gastric cancer risk from H. pylori is at least 50 per 100,000 per year, but the esophageal risk of not having H. pylori is much lower, only 4.27 So at the moment, there is a ten-fold benefit from H. pylori eradication. Of course if the patient has symptomatic heartburn, we can easily control this with a proton pump inhibitor, so this risk of acidity is probably low.
The future of H. pylori management might rely on a successful vaccine. There are many unique outer membrane proteins that can be used as vaccine targets in H . pylori. Ideally, we want the presence of the antigen in all strains of H. pylori. Although the essential genome of H. pylori is only about 750 genes, Covacci's group believe that the Cag-PAI-positive H. pylori is the most important to eradicate, so they have incorporated a CagA antigen in their vaccine." The Urel is probably also a good vaccine candidate because it must be partly exposed on the surface of the H. pylori.
A typical vaccine experiment is usually first performed in mice. Covacci's group has a vaccine against neutrophil attracting protein (NAP), which gives considerable protection from H. pylori. They have also seen 80% protection with CagA and with whole organisms they see 90% protection. A new vaccine combining three antigens is as effective as the whole bacterium vaccine . 28 At the present time, studies in healthy, normal persons with H. pylori are under way. However, it is likely to be at least ten more years before we can see a useful vaccine for H. pylori.
Origins of H. pylori
Where does H. pylori come from? Recent data suggests that it followed humans out of Africa into Europe, and eventually to China about 20,000 years ago. Strains in Europe can be identified as type I compared with Japanese/Chinese strains, which are called type 11.21 But one of the questions is, "Are strains in Brazil and Venezuela European or Asian?" We now know that the strains of H. pylori in very remote South American Indian tribes actually resemble Asian strains." This suggests that H. pylori has been migrating with humans over the past 30,000 years. Nowadays, most people in America have a Spanish or European strain, but probably that has just replaced the Asian strain.
Transmission of H. pylori
We still do not know exactly how H. pylori is transmitted. One of the ways that we can study the epidemiology is with a swallowed string. One hour after swallowing the string, we pull the string out of the patient's mouth. Adhering to the lower end we now have culturable H. pylori. Recently we studied married couples that were both infected with H. pylori. By using AFLP techniques, we could show that strains from the wife were almost identical to the husband's strains. So it appears that some couples are behaving like a single culture medium with the same strain of H. pylori moving between them. Maybe H. pylori can be spread in families by kissing, but there is still a lot of controversy about his theory.
Cost Effectiveness of H. pylori Eradication
Finally, let us consider the issue of whether it is cost effective to eradicate H. pylori in the whole population. In this analysis, I will compare H. pylori to dandruff, which is a common scaly scalp condition. Both of these diseases are chronic inflammatory processes, often asymptomatic, with a known microbial agent. Dandruff is caused by a fungus and gastritis is caused by H. pylori. Reasons for therapy in both are cosmetic; i.e. white flakes in the scalp, or redness with bad histology in the stomach. But the cost of treatment is much higher for dandruff. Using over-the-counter medication, sufferers might spend USD$15 a month, or USD$1,500 over ten years. So USD$1500 is the lifetime cost of treating dandruff, yet many people in the population choose to buy dandruff treatment.
If you ask these same people if they would like to take a treatment that could decrease cancer in the Japanese population and only cost USD$100, they might perceive this as even better value than treating dandruff. On a cost effectiveness assessment, particularly in Japan, eradication of H. pylori seems advisable as soon as we obtain confirmatory evidence that H. pylori eradication prevents cancer. Policymakers will soon realize that it is very good value to eradicate H. pylori in Japan.
